dgk inhibitor

R59949 is used as a Diacylglycerol kinase (DGK) inhibitor.

Dioctanoylglycol (ethane-1,2-diyl dioctanoate) is a diacylglycerol kinase inhibitor.

BMS-502 is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ that induces immune responses in human and mouse T cells and blocks intracellular checkpoint signaling in T cells. BMS-502 stimulates immune responses in a dose-dependent manner and can be used to study immune-related diseases.

R 59-022 hydrochloride (DKGI-I hydrochloride) is a 5-HT Receptor antagonist that activates protein kinase C (PKC).R 59-022 hydrochloride is a DGK inhibitor (IC50:2.8 µM) that inhibits the phosphorylation of OAG to OAPA.R 59-022 enhances thrombin-induced triglyceride production in platelets and inhibits the production of phosphatidic acid in neutrophils. R 59-022 enhances thrombin-induced diglyceride production in platelets and inhibits phosphatidic acid production in neutrophils.

DGKζ-IN-4, a DGK-zeta inhibitor, is utilized as an active ingredient in pharmaceutical formulations to treat cancers associated with immune cell activation or those resistant to anti-PD-1 anti-PD-L1 antibody treatments [1].

Cochlioquinone A is an inhibitor of diacylglycerol kinase (DGK) and diacylglycerol acyltransferase (DGAT). It has been shown to reduce the concentration of phosphatidic acid in T cell lymphoma and has also been shown to compete with macrophage inflammatory protein-1α for binding to human CCR5 chemokine receptors.

BMS-986408 is a DGK α Zeta dual inhibitor with oral bioavailability. Can be used for anti-tumor related research.

R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

DGKα&ζ-IN-1 (Compound II) is a DGK inhibitor that enhances T-cell function and synergistically interacts with PD-1, providing therapeutic advantages in immune and tumor contexts [1].

DGKζ-IN-3 is an inhibitor of diacylglycerol kinase zeta (DGK-ζ), employed in the treatment of both liquid and solid cancers, as well as other diseases regulated by DGK-ζ [1].